All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Eli Muchtar, Mayo Clinic, Rochester, US and Suzanne Lentzsch, Columbia University, New York, US. We asked, The challenges of monitoring organ response in AL amyloidosis: What has been achieved so far?
The challenges of monitoring organ response in AL amyloidosis: What has been achieved so far?
The podcast focuses on both hematologic and organ response in amyloidosis, as well discussing the findings of a recent study.
Your opinion matters
Could bendamustine plus dexamethasone be a viable treatment option for R/R systemic light-chain amyloidosis?
Results of phase IIa multicenter study conducted to determine the efficacy and safety of bendamustine plus dexamethasone in patients with...
How should we treat AL amyloidosis in 2019?
Suzanne Lentzsch from Columbia University, New York, spoke to the Multiple Myeloma Hub about the treatment of AL amyloidosis in 2019 and the importance of correct diagnosis and confirmation.
Subscribe to get the best content related to multiple myeloma delivered to your inbox